Molecular basis and clinical features of nephrogenic diabetes insipidus

References

• Forssman H. The recognition of nephrogenic diabetes insipidus. A very small page from the history of medicine. Acta Med. Scand.197(1–2), 1–6 (1975).
   Google Scholar
• Cannon JF. Diabetes insipidus; clinical and experimental studies with consideration of genetic relationships. AMA Arch. Intern. Med.96(2), 215–272 (1955).
   Google Scholar
• Bode HH, Crawford JD. Nephrogenic diabetes insipidus in North America. The Hopewell hypothesis. N. Engl. J. Med.280(14), 750–754 (1969).
   Google Scholar
• Bichet DG, Razi M, Arthus MF et al. Epinephrine and dDAVP administration in patients with congenital nephrogenic diabetes insipidus. Evidence for a pre-cyclic AMP V2 receptor defective mechanism. Kidney Int.36(5), 859–866 (1989).
   Google Scholar
• Jans DA, van Oost BA, Ropers HH, Fahrenholz F. Derivatives of somatic cell hybrids which carry the human gene locus for nephrogenic diabetes insipidus (NDI) express functional vasopressin renal V2-type receptors. J. Biol. Chem.265(26), 15379–15382 (1990).
   Google Scholar
• Rosenthal W, Seibold A, Antaramian A et al. Molecular identification of the gene responsible for congenital nephrogenic diabetes insipidus. Nature359(6392), 233–235 (1992).
   PubMed Web of Science ®Google Scholar
• Birnbaumer M, Seibold A, Gilbert S et al. Molecular cloning of the receptor for human antidiuretic hormone. Nature357(6376), 333–335 (1992).
   PubMed Web of Science ®Google Scholar
• van den Ouweland AM, Dreesen JC, Verdijk M et al. Mutations in the vasopressin type 2 receptor gene (AVPR2) associated with nephrogenic diabetes insipidus. Nat. Genet.2(2), 99–102 (1992).
   Google Scholar
• Deen PM, Verdijk MA, Knoers NV et al. Requirement of human renal water channel aquaporin-2 for vasopressin-dependent concentration of urine. Science264(5155), 92–95 (1994).
   PubMed Web of Science ®Google Scholar
• Mulders SM, Bichet DG, Rijss JP et al. An aquaporin-2 water channel mutant which causes autosomal dominant nephrogenic diabetes insipidus is retained in the Golgi complex. J. Clin. Invest.102(1), 57–66 (1998).
   Google Scholar
• Robertson GL. Differential diagnosis of polyuria. Annu. Rev. Med.39, 425–442 (1988).
   PubMed Web of Science ®Google Scholar
• van Lieburg AF, Knoers NV, Monnens LA. Clinical presentation and follow-up of 30 patients with congenital nephrogenic diabetes insipidus. J. Am. Soc. Nephrol.10(9), 1958–1964 (1999).
   PubMed Web of Science ®Google Scholar
• Kanno K, Sasaki S, Hirata Y et al. Urinary excretion of aquaporin-2 in patients with diabetes insipidus. N. Engl. J. Med.332(23), 1540–1545 (1995).
   PubMed Web of Science ®Google Scholar
• Deen PM, van Aubel RA, van Lieburg AF, van Os CH. Urinary content of aquaporin 1 and 2 in nephrogenic diabetes insipidus. J. Am. Soc. Nephrol.7(6), 836–841 (1996).
   Google Scholar
• Sadeghi H, Robertson GL, Bichet DG, Innamorati G, Birnbaumer M. Biochemical basis of partial nephrogenic diabetes insipidus phenotypes. Mol. Endocrinol.11(12), 1806–1813 (1997).
   PubMedGoogle Scholar
• Ala Y, Morin D, Mouillac B et al. Functional studies of twelve mutant V2 vasopressin receptors related to nephrogenic diabetes insipidus: molecular basis of a mild clinical phenotype. J. Am. Soc. Nephrol.9(10), 1861–1872 (1998).
   Google Scholar
• Boccalandro C, De Mattia F, Guo DC et al. Characterization of an aquaporin-2 water channel gene mutation causing partial nephrogenic diabetes insipidus in a Mexican family: evidence of increased frequency of the mutation in the town of origin. J. Am. Soc. Nephrol.15(5), 1223–1231 (2004).
   Google Scholar
• van Lieburg AF, Verdijk MA, Schoute F et al. Clinical phenotype of nephrogenic diabetes insipidus in females heterozygous for a vasopressin type 2 receptor mutation. Hum. Genet.96(1), 70–78 (1995).
   PubMed Web of Science ®Google Scholar
• Nomura Y, Onigata K, Nagashima T et al. Detection of skewed X-inactivation in two female carriers of vasopressin type 2 receptor gene mutation. J. Clin. Endocrinol. Metab.82(10), 3434–3437 (1997).
   PubMed Web of Science ®Google Scholar
• Kinoshita K, Miura Y, Nagasaki H et al. A novel deletion mutation in the arginine vasopressin receptor 2 gene and skewed X chromosome inactivation in a female patient with congenital nephrogenic diabetes insipidus. J. Endocrinol. Invest.27(2), 167–170 (2004).
   Google Scholar
• Pasel K, Schulz A, Timmermann K et al. Functional characterization of the molecular defects causing nephrogenic diabetes insipidus in eight families. J. Clin. Endocrinol. Metab.85(4), 1703–1710 (2000).
   PubMed Web of Science ®Google Scholar
• Uribarri J, Kaskas M. Hereditary nephrogenic diabetes insipidus and bilateral nonobstructive hydronephrosis. Nephron65(3), 346–349 (1993).
   PubMed Web of Science ®Google Scholar
• Nakada T, Miyauchi T, Sumiya H, Shimazaki J. Nonobstructive urinary tract dilatation in nephrogenic diabetes insipidus. Int. Urol. Nephrol.22(5), 419–427 (1990).
   Google Scholar
• Shalev H, Romanovsky I, Knoers NV, Lupa S, Landau D. Bladder function impairment in aquaporin-2 defective nephrogenic diabetes insipidus. Nephrol. Dial. Transplant.19(3), 608–613 (2004).
   PubMed Web of Science ®Google Scholar
• Ulinski T, Grapin C, Forin V et al. Severe bladder dysfunction in a family with ADH receptor gene mutation responsible for X-linked nephrogenic diabetes insipidus. Nephrol. Dial. Transplant.19(11), 2928–2929 (2004).
   Google Scholar
• Zender HO, Ruedin P, Moser F, Bolle JF, Leski M. Traumatic rupture of the urinary tract in a patient presenting nephrogenic diabetes insipidus associated with hydronephrosis and chronic renal failure: case report and review of the literature. Clin. Nephrol.38(4), 196–202 (1992).
   Google Scholar
• Mendonca EV, Stone RC, Rosa FC. Prevention of intracranial calcifications and brain damage associated with nephrogenic diabetes insipidus. Pediatr. Nephrol.8(2), 263 (1994).
   Google Scholar
• Schofer O, Beetz R, Bohl J et al. Mental retardation syndrome with renal concentration deficiency and intracerebral calcification. Eur. J. Pediatr.149(7), 470–474 (1990).
   Google Scholar
• Zaki M, Schöneberg T, Al Ajrawi T et al. Nephrogenic diabetes insipidus, thiazide treatment and renal cell carcinoma. Nephrol. Dial. Transplant.21(4), 1082–1086 (2006).
   Google Scholar
• Ray M, Dixit A, Singhi P. Nephrogenic diabetes insipidus with intracranial calcifications. Indian Pediatr.39(2), 197–202 (2002).
   Google Scholar
• Nozue T, Uemasu F, Endoh H et al. Intracranial calcifications associated with nephrogenic diabetes insipidus. Pediatr. Nephrol.7(1), 74–76 (1993).
   Google Scholar
• Tohyama J, Inagaki M, Koeda T, Ohno K, Takeshita K. Intracranial calcification in siblings with nephrogenic diabetes insipidus: CT and MRI. Neuroradiology35(7), 553–555 (1993).
   Google Scholar
• Di Rocco M, Picco P, Gandullia P, Borrone C. Intracranial calcifications and nephrogenic diabetes insipidus. Eur. J. Pediatr.150(8), 599–600 (1991).
   Google Scholar
• Freycon MT, Lavocat MP, Freycon F. Familial nephrogenic diabetes insipidus with chronic hypernatremia and cerebral calcifications. Pediatrie43(5), 409–413 (1988).
   Google Scholar
• Kanzaki S, Omura T, Miyake M et al. Intracranial calcification in nephrogenic diabetes insipidus. JAMA254(23), 3349–3350 (1985).
   Google Scholar
• Bagga A, Kumar A, Bajaj G, Gupta A, Srivastava RN. Intracranial calcification in nephrogenic diabetes insipidus. Clin. Pediatr. (Phila.)35(1), 34–36 (1996).
   Google Scholar
• Nunes ML, da Costa JC, Severini MH. Early onset bilateral calcifications and epilepsy. Pediatr. Neurol.13(1), 80–82 (1995).
   Google Scholar
• Forssman H. Is hereditary diabetes insipidus of nephrogenic type associated with mental deficiency? Acta Psychiatr. Neurol. Scand.30(4), 577–587 (1955).
   Google Scholar
• Hoekstra JA, van Lieburg AF, Monnens LA, Hulstijn-Dirkmaat GM, Knoers VV. Cognitive and psychosocial functioning of patients with congenital nephrogenic diabetes insipidus. Am. J. Med. Genet.61(1), 81–88 (1996).
   Google Scholar
• Comacchio F, Boggian O, Poletto E et al. Meniere’s disease in congenital nephrogenic diabetes insipidus: report of two twins. Am. J. Otol.13(5), 477–481 (1992).
   Google Scholar
• Schulz A, Sangkuhl K, Lennert T et al. Aminoglycoside pretreatment partially restores the function of truncated V(2) vasopressin receptors found in patients with nephrogenic diabetes insipidus. J. Clin. Endocrinol. Metab.87(11), 5247–5257 (2002).
   Google Scholar
• Schmieder RE, Delles C, Messerli FH. Diuretic therapy and the risk for renal cell carcinoma. J. Nephrol.13(5), 343–346 (2000).
   Google Scholar
• Messerli FH. Risk factors for renal cell carcinoma: hypertension or diuretics? Kidney Int.67(2), 774–775 (2005).
   PubMed Web of Science ®Google Scholar
• Liu J, Wess J. Different single receptor domains determine the distinct G protein coupling profiles of members of the vasopressin receptor family. J. Biol. Chem.271(15), 8772–8778 (1996).
   Web of Science ®Google Scholar
• Ecelbarger CA, Chou CL, Lolait SJ, Knepper MA, DiGiovanni SR. Evidence for dual signaling pathways for V2 vasopressin receptor in rat inner medullary collecting duct. Am J. Physiol.270(4 Pt 2), F623–F633 (1996).
   Google Scholar
• Kojro E, Fahrenholz F. Ligand-induced cleavage of the V2 vasopressin receptor by a plasma membrane metalloproteinase. J. Biol. Chem.270(12), 6476–6481 (1995).
   PubMed Web of Science ®Google Scholar
• Kojro E, Postina R, Gilbert S et al. Structural requirements for V2 vasopressin receptor proteolytic cleavage. Eur. J. Biochem.266(2), 538–548 (1999).
   Google Scholar
• Sadeghi H, Birnbaumer M. O-Glycosylation of the V2 vasopressin receptor. Glycobiology,9(7), 731–737 (1999).
   Google Scholar
• Sadeghi HM, Innamorati G, Dagarag M, Birnbaumer M. Palmitoylation of the V2 vasopressin receptor. Mol. Pharmacol.52(1), 21–29 (1997).
   PubMed Web of Science ®Google Scholar
• Ren XR, Reiter E, Ahn S et al. Different G protein-coupled receptor kinases govern G protein and β-arrestin-mediated signaling of V2 vasopressin receptor. Proc. Natl Acad. Sci. USA102(5), 1448–1453 (2005).
   PubMed Web of Science ®Google Scholar
• Terrillon S, Durroux T, Mouillac B et al. Oxytocin and vasopressin V1a and V2 receptors form constitutive homo- and heterodimers during biosynthesis. Mol. Endocrinol.17(4), 677–691 (2003).
   PubMed Web of Science ®Google Scholar
• Schulz A, Grosse R, Schultz G, Gudermann T, Schöneberg T. Structural implication for receptor oligomerization from functional reconstitution studies of mutant V2 vasopressin receptors. J. Biol. Chem.275(4), 2381–2389 (2000).
   Google Scholar
• Schöneberg T, Schulz A, Biebermann H et al. Mutant G-protein-coupled receptors as a cause of human diseases. Pharmacol. Ther.104(3), 173–206 (2004).
   PubMed Web of Science ®Google Scholar
• Cooper DN, Krawczak M. Cytosine methylation and the fate of CpG dinucleotides in vertebrate genomes. Hum. Genet.83(2), 181–188 (1989).
   PubMed Web of Science ®Google Scholar
• Sangkuhl K, Rompler H, Busch W, Karges B, Schöneberg T. Nephrogenic diabetes insipidus caused by mutation of Tyr205: a key residue of V2 vasopressin receptor function. Hum. Mutat.25(5), 505 (2005).
   Google Scholar
• Schülein R, Zuhlke K, Krause G, Rosenthal W. Functional rescue of the nephrogenic diabetes insipidus-causing vasopressin V2 receptor mutants G185C and R202C by a second site suppressor mutation. J. Biol. Chem.276(11), 8384–8392 (2001).
   Google Scholar
• Erlenbach I, Wess J. Molecular basis of V2 vasopressin receptor/Gs coupling selectivity. J. Biol. Chem.273(41), 26549–26558 (1998).
   Google Scholar
• Leanos-Miranda A, Janovick JA, Conn PM. Receptor-misrouting: an unexpectedly prevalent and rescuable etiology in gonadotropin-releasing hormone receptor-mediated hypogonadotropic hypogonadism. J. Clin. Endocrinol. Metab.87(10), 4825–4828 (2002).
   PubMed Web of Science ®Google Scholar
• Schülein R. The early stages of the intracellular transport of membrane proteins: clinical and pharmacological implications. Rev. Physiol. Biochem. Pharmacol.151, 45–91 (2004).
   Google Scholar
• Morello JP, Salahpour A, Petaja-Repo UE et al. Association of calnexin with wild type and mutant AVPR2 that causes nephrogenic diabetes insipidus. Biochemistry40(23), 6766–6775 (2001).
   PubMed Web of Science ®Google Scholar
• Schöneberg T, Schulz A, Biebermann H et al. V2 vasopressin receptor dysfunction in nephrogenic diabetes insipidus caused by different molecular mechanisms. Hum. Mutat.12(3), 196–205 (1998).
   Google Scholar
• Feldman BJ, Rosenthal SM, Vargas GA et al. Nephrogenic syndrome of inappropriate antidiuresis. N. Engl. J. Med.352(18), 1884–1890 (2005).
   PubMed Web of Science ®Google Scholar
• Rosenthal W, Seibold A, Antaramian A et al. Mutations in the vasopressin V2 receptor gene in families with nephrogenic diabetes insipidus and functional expression of the Q-2 mutant. Cell Mol. Biol. (Noisy-le-grand)40(3), 429–436 (1994).
   PubMed Web of Science ®Google Scholar
• Shoji Y, Takahashi T, Suzuki Y et al. Mutational analyses of AVPR2 gene in three Japanese families with X-linked nephrogenic diabetes insipidus: two recurrent mutations, R137H and deltaV278, caused by the hypermutability at CpG dinucleotides. Hum. Mutat.1(Suppl.), S278–S283 (1998).
   Google Scholar
• Schöneberg T, Pasel K, von Baehr V et al. Compound deletion of the rhoGAP C1 and V2 vasopressin receptor genes in a patient with nephrogenic diabetes insipidus. Hum. Mutat.14(2), 163–174 (1999).
   Google Scholar
• Demura M, Takeda Y, Yoneda T et al. Two novel types of contiguous gene deletion of the AVPR2 and ARHGAP4 genes in unrelated Japanese kindreds with nephrogenic diabetes insipidus. Hum. Mutat.19(1), 23–29 (2002).
   Google Scholar
• Tribioli C, Droetto S, Bione S et al. An X chromosome-linked gene encoding a protein with characteristics of a rhoGAP predominantly expressed in hematopoietic cells. Proc. Natl Acad. Sci. USA93(2), 695–699 (1996).
   PubMedGoogle Scholar
• Foletta VC, Brown FD, Young WS 3rd. Cloning of rat ARHGAP4/C1, a RhoGAP family member expressed in the nervous system that colocalizes with the Golgi complex and microtubules. Brain Res. Mol. Brain Res.107(1), 65–79 (2002).
   Google Scholar
• Christerson LB, Gallagher E, Vanderbilt CA et al. p115 Rho GTPase activating protein interacts with MEKK1. J. Cell Physiol.192(2), 200–208 (2002).
   PubMedGoogle Scholar
• Arthus MF, Lonergan M, Crumley MJ et al. Report of 33 novel AVPR2 mutations and analysis of 117 families with X-linked nephrogenic diabetes insipidus. J. Am. Soc. Nephrol.11(6), 1044–1054 (2000).
   PubMed Web of Science ®Google Scholar
• Kamperis K, Siggaard C, Herlin T et al. A novel splicing mutation in the V2 vasopressin receptor. Pediatr. Nephrol.15(1–2), 43–49 (2000).
   PubMed Web of Science ®Google Scholar
• Verkman AS. Novel roles of aquaporins revealed by phenotype analysis of knockout mice. Rev. Physiol. Biochem. Pharmacol.155, 31–55 (2005).
   PubMedGoogle Scholar
• Nielsen S, Chou CL, Marples D et al. Vasopressin increases water permeability of kidney collecting duct by inducing translocation of aquaporin-CD water channels to plasma membrane. Proc. Natl Acad. Sci. USA92(4), 1013–1017 (1995).
   PubMed Web of Science ®Google Scholar
• Klussmann E, Maric K, Wiesner B, Beyermann M, Rosenthal W. Protein kinase A anchoring proteins are required for vasopressin-mediated translocation of aquaporin-2 into cell membranes of renal principal cells. J. Biol. Chem.274(8), 4934–4938 (1999).
   PubMedGoogle Scholar
• Kuwahara M, Fushimi K, Terada Y et al. cAMP-dependent phosphorylation stimulates water permeability of aquaporin-collecting duct water channel protein expressed in Xenopus oocytes. J. Biol. Chem.270(18), 10384–10387 (1995).
   PubMed Web of Science ®Google Scholar
• Kamsteeg EJ, Heijnen I, van Os CH, Deen PM. The subcellular localization of an aquaporin-2 tetramer depends on the stoichiometry of phosphorylated and nonphosphorylated monomers. J. Cell Biol.151(4), 919–930 (2000).
   PubMed Web of Science ®Google Scholar
• Noda Y, Sasaki S. Regulation of aquaporin-2 trafficking and its binding protein complex. Biochim. Biophys. Acta1758(8), 1117–1125 (2006).
   PubMedGoogle Scholar
• Deen PM, van Balkom BW, Kamsteeg EJ. Routing of the aquaporin-2 water channel in health and disease. Eur. J. Cell Biol.79(8), 523–530 (2000).
   Google Scholar
• de Mattia F, Savelkoul PJ, Bichet DG et al. A novel mechanism in recessive nephrogenic diabetes insipidus: wild-type aquaporin-2 rescues the apical membrane expression of intracellularly retained AQP2-P262L. Hum. Mol. Genet.13(24), 3045–3056 (2004).
   Google Scholar
• Deen PM, Croes H, van Aubel RA, Ginsel LA, van Os CH. Water channels encoded by mutant aquaporin-2 genes in nephrogenic diabetes insipidus are impaired in their cellular routing. J. Clin. Invest.95(5), 2291–2296 (1995).
   PubMed Web of Science ®Google Scholar
• Kamsteeg EJ, Bichet DG, Konings IB et al. Reversed polarized delivery of an aquaporin-2 mutant causes dominant nephrogenic diabetes insipidus. J. Cell Biol.163(5), 1099–1109 (2003).
   Google Scholar
• Kamsteeg EJ, Wormhoudt TA, Rijss JP, van Os CH, Deen PM. An impaired routing of wild-type aquaporin-2 after tetramerization with an aquaporin-2 mutant explains dominant nephrogenic diabetes insipidus. EMBO J.18(9), 2394–2400 (1999).
   PubMedGoogle Scholar
• Marr N, Bichet DG, Lonergan M et al. Heteroligomerization of an aquaporin-2 mutant with wild-type aquaporin-2 and their misrouting to late endosomes/lysosomes explains dominant nephrogenic diabetes insipidus. Hum. Mol. Genet.11(7), 779–789 (2002).
   PubMedGoogle Scholar
• de Mattia F, Savelkoul PJ, Kamsteeg EJ et al. Lack of arginine vasopressin-induced phosphorylation of aquaporin-2 mutant AQP2-R254L explains dominant nephrogenic diabetes insipidus. J. Am. Soc. Nephrol.16(10), 2872–2880 (2005).
   Google Scholar
• Naik DV, Valtin H. Hereditary vasopressin-resistant urinary concentrating defects in mice. Am J. Physiol.217(4), 1183–1190 (1969).
   Google Scholar
• Luzius H, Jans DA, Grunbaum EG et al. A low affinity vasopressin V2-receptor in inherited nephrogenic diabetes insipidus. J. Recept. Res.12(3), 351–368 (1992).
   PubMed Web of Science ®Google Scholar
• Braun EJ, Stallone JN. The occurrence of nephrogenic diabetes insipidus in domestic fowl. Am. J. Physiol.256(4 Pt 2), F639–F645 (1989).
   Google Scholar
• Singer I, Rotenberg D, Puschett JB. Lithium-induced nephrogenic diabetes insipidus: in vivo and in vitro studies. J. Clin. Invest.51(5), 1081–1091 (1972).
   PubMed Web of Science ®Google Scholar
• Yun J, Schöneberg T, Liu J et al. Generation and phenotype of mice harboring a nonsense mutation in the V2 vasopressin receptor gene. J. Clin. Invest.106(11), 1361–1371 (2000).
   Google Scholar
• Yang B, Gillespie A, Carlson EJ, Epstein CJ, Verkman AS. Neonatal mortality in an aquaporin-2 knock-in mouse model of recessive nephrogenic diabetes insipidus. J. Biol. Chem.276(4), 2775–2779 (2001).
   PubMed Web of Science ®Google Scholar
• Yang B, Zhao D, Qian L, Verkman AS. Mouse model of inducible nephrogenic diabetes insipidus produced by floxed aquaporin-2 gene deleltion. Am. J. Physiol. Renal Physiol.291(2), F465–F472 (2006).
   Google Scholar
• Lloyd DJ, Hall FW, Tarantino LM, Gekakis N. Diabetes insipidus in mice with a mutation in aquaporin-2. PLoS Genet.1(2), E20 (2005).
   Google Scholar
• McDill BW, Li SZ, Kovach PA, Ding L, Chen F. Congenital progressive hydronephrosis (cph) is caused by an S256L mutation in aquaporin-2 that affects its phosphorylation and apical membrane accumulation. Proc. Natl Acad. Sci. USA103(18), 6952–6957 (2006).
   PubMed Web of Science ®Google Scholar
• Padfield PL, Morton JJ, Lindop G, Timbury GC. Lithium induced nephrogenic diabetes insipidus: changes in plasma vasopressin and angiotensin II. Clin. Nephrol.3(6), 220–224 (1975).
   Google Scholar
• Padfield PL, Park SJ, Morton JJ, Braidwood AE. Plasma levels of antidiuretic hormone in patients receiving prolonged lithium therapy. Br. J. Psychiatry130, 144–147 (1977).
   Google Scholar
• Bichet DG, Razi M, Lonergan M et al. Hemodynamic and coagulation responses to 1-desamino[8-D-arginine] vasopressin in patients with congenital nephrogenic diabetes insipidus. N. Engl. J. Med.318(14), 881–887 (1988).
   PubMed Web of Science ®Google Scholar
• Tanoue A, Ito S, Honda K et al. The vasopressin V1b receptor critically regulates hypothalamic–pituitary–adrenal axis activity under both stress and resting conditions. J. Clin. Invest.113(2), 302–309 (2004).
   PubMed Web of Science ®Google Scholar
• Wersinger SR, Ginns EI, O’Carroll AM, Lolait SJ, Young WS 3rd. Vasopressin V1b receptor knockout reduces aggressive behavior in male mice. Mol. Psychiatry7(9), 975–984 (2002).
   PubMed Web of Science ®Google Scholar
• Khokhar AM, Slater JD, Ma J, Ramage CM. The cardiovascular effect of vasopressin in relation to its plasma concentration in man and its relevance to high blood pressure. Clin. Endocrinol. (Oxf.)13(3), 259–266 (1980).
   Google Scholar
• Bichet DG, Arthus MF, Lonergan M. Platelet vasopressin receptors in patients with congenital nephrogenic diabetes insipidus. Kidney Int.39(4), 693–699 (1991).
   Google Scholar
• Sangkuhl K, Schulz A, Römpler H et al. Aminoglycoside-mediated rescue of a disease-causing nonsense mutation in the V2 vasopressin receptor gene in vitro and in vivo. Hum. Mol. Genet.13(9), 893–903 (2004).
   Google Scholar
• Kim YH, Kwon TH, Christensen BM et al. Altered expression of renal acid-base transporters in rats with lithium-induced NDI. Am. J. Physiol. Renal Physiol.285(6), F1244–F1257 (2003).
   Google Scholar
• Kwon TH, Laursen UH, Marples D et al. Altered expression of renal AQPs and Na+ transporters in rats with lithium-induced NDI. Am. J. Physiol. Renal Physiol.279(3), F552–F564 (2000).
   PubMed Web of Science ®Google Scholar
• Dembowski J, Gekle D, Thoenes W, Wernze H. Hyperreninism and hypertrophy of the juxtaglomerular apparatus in familial nephrogenic diabetes insipidus. Klin. Wochenschr.51(23), 1159–1163 (1973).
   Google Scholar
• Saruta T, Fujimaki M, Ogihara T et al. Evaluation of the renin-angiotensin system in diabetes insipidus and psychogenic polydipsia. Nephron32(1), 14–17 (1982).
   Google Scholar
• Minami J, On K, Inada H et al. A case of congenital nephrogenic diabetes insipidus accompanied by hypertension. Nippon Jinzo Gakkai Shi43(1), 35–38 (2001).
   Google Scholar
• Balment RJ, Jones IC, Henderson IW. Time course of lithium-induced alterations in renal and endocrine function in normal and Brattleboro rats with hypothalamic diabetes insipidus. Br. J. Pharmacol.59(4), 627–634 (1977).
   Google Scholar
• Wilson TW. Renal prostaglandin synthesis and angiotensin-converting enzyme inhibition. J. Cardiovasc. Pharmacol.19(Suppl. 6), S39–S44 (1992).
   Google Scholar
• Friis-Hansen B, Skadhauge E, Zetterstroem R. Fluid and electrolyte metabolism in nephrogenic diabetes insipidus. Two cases. Acta Paediatr.146(Suppl.), 157–167 (1963).
   Google Scholar
• Kuzemko JA, Robson JE. Chlorothiazide in the treatment of nephrogenic diabetes insipidus. Br. J. Clin. Pract.20(10), 521–524 (1966).
   Google Scholar
• Goldfarb DS, Chan AJ, Hernandez D, Charney AN. Effect of thiazides on colonic NaCl absorption: role of carbonic anhydrase. Am J. Physiol.261(3 Pt 2), F452–F458 (1991).
   Google Scholar
• Meyerson LR, Nesta D. [3H]acetazolamide binding to carbonic anhydrase in normal and transformed cells. Biochem. Pharmacol.41(6–7), 995–1000 (1991).
   Google Scholar
• Konoshita T, Kuroda M, Kawane T et al. Treatment of congenital nephrogenic diabetes insipidus with hydrochlorothiazide and amiloride in an adult patient. Horm. Res.61(2), 63–67 (2004).
   Google Scholar
• Kirchlechner V, Koller DY, Seidl R, Waldhauser F. Treatment of nephrogenic diabetes insipidus with hydrochlorothiazide and amiloride. Arch. Dis. Child.80(6), 548–552 (1999).
   Google Scholar
• Uyeki TM, Barry FL, Rosenthal SM, Mathias RS. Successful treatment with hydrochlorothiazide and amiloride in an infant with congenital nephrogenic diabetes insipidus. Pediatr. Nephrol.7(5), 554–556 (1993).
   Google Scholar
• Alon U, Chan JC. Hydrochlorothiazide-amiloride in the treatment of congenital nephrogenic diabetes insipidus. Am. J. Nephrol.5(1), 9–13 (1985).
   Google Scholar
• Rascher W, Rosendahl W, Henrichs IA, Maier R, Seyberth HW. Congenital nephrogenic diabetes insipidus-vasopressin and prostaglandins in response to treatment with hydrochlorothiazide and indomethacin. Pediatr. Nephrol.1(3), 485–490 (1987).
   Google Scholar
• Kaulitz R, Brodehl J. Long-term course of 6 boys with congenital nephrogenic diabetes insipidus. Klin. Padiatr.201(6), 425–430 (1989).
   Google Scholar
• Pattaragarn A, Alon US. Treatment of congenital nephrogenic diabetes insipidus by hydrochlorothiazide and cyclooxygenase-2 inhibitor. Pediatr. Nephrol.18(10), 1073–1076 (2003).
   PubMed Web of Science ®Google Scholar
• Soylu A, Kasap B, Ogun N et al. Efficacy of COX-2 inhibitors in a case of congenital nephrogenic diabetes insipidus. Pediatr. Nephrol.20(12), 1814–1817 (2005).
   Google Scholar
• Dies F, Suarez MA, Rivera A. Treatment of diabetes insipidus with orally administered compounds. Clin. Pharmacol. Ther.12, 602–611 (1963).
   Google Scholar
• Cenani A, Friederiszick FK. Familial renal diabetes insipidus. Z. Kinderheilkd.88, 329–346 (1963).
   Google Scholar
• Nielsen J, Kwon TH, Praetorius J et al. Aldosterone increases urine production and decreases apical AQP2 expression in rats with diabetes insipidus. Am. J. Physiol. Renal Physiol.290(2), F438–F449 (2006).
   Google Scholar
• Coffey AK, O’Sullivan DJ, Homma S, Dousa TP, Valtin H. Induction of intramembranous particle clusters in mice with nephrogenic diabetes insipidus. Am. J. Physiol.261(4 Pt 2), F640–F646 (1991).
   Google Scholar
• Bichet DG, Ruel N, Arthus MF, Lonergan M. Rolipram, a phosphodiesterase inhibitor, in the treatment of two male patients with congenital nephrogenic diabetes insipidus. Nephron56(4), 449–450 (1990).
   Google Scholar
• Bouley R, Breton S, Sun T et al. Nitric oxide and atrial natriuretic factor stimulate cGMP-dependent membrane insertion of aquaporin 2 in renal epithelial cells. J. Clin. Invest.106(9), 1115–1126 (2000).
   PubMed Web of Science ®Google Scholar
• Brown D. The ins and outs of aquaporin-2 trafficking. Am. J. Physiol. Renal Physiol.284(5), F893–F901 (2003).
   PubMedGoogle Scholar
• Bouley R, Pastor-Soler N, Cohen O et al. Stimulation of AQP2 membrane insertion in renal epithelial cells in vitro and in vivo by the cGMP phosphodiesterase inhibitor sildenafil citrate (Viagra). Am. J. Physiol. Renal Physiol.288(6), F1103–F1112 (2005).
   Google Scholar
• Tamarappoo BK, Verkman AS. Defective aquaporin-2 trafficking in nephrogenic diabetes insipidus and correction by chemical chaperones. J. Clin. Invest.101(10), 2257–2267 (1998).
   PubMed Web of Science ®Google Scholar
• Tamarappoo BK, Yang B, Verkman AS. Misfolding of mutant aquaporin-2 water channels in nephrogenic diabetes insipidus. J. Biol. Chem.274(49), 34825–34831 (1999).
   Google Scholar
• Morello JP, Salahpour A, Laperriere A et al. Pharmacological chaperones rescue cell-surface expression and function of misfolded V2 vasopressin receptor mutants. J. Clin. Invest.105(7), 887–895 (2000).
   PubMed Web of Science ®Google Scholar
• Wüller S, Wiesner B, Löffler A et al. Pharmacochaperones post-translationally enhance cell surface expression by increasing conformational stability of wild-type and mutant vasopressin V2 receptors. J. Biol. Chem.279(45), 47254–47263 (2004).
   PubMed Web of Science ®Google Scholar
• Bernier V, Lagace M, Lonergan M et al. Functional rescue of the constitutively internalized V2 vasopressin receptor mutant R137H by the pharmacological chaperone action of SR49059. Mol. Endocrinol.18(8), 2074–2084 (2004).
   Google Scholar
• Bernier V, Morello JP, Zarruk A et al. Pharmacologic chaperones as a potential treatment for X-linked nephrogenic diabetes insipidus. J. Am. Soc. Nephrol.17(1), 232–243 (2006).
   PubMed Web of Science ®Google Scholar
• Wilschanski M, Yahav Y, Yaacov Y et al. Gentamicin-induced correction of CFTR function in patients with cystic fibrosis and CFTR stop mutations. N. Engl. J. Med.349(15), 1433–1441 (2003).
   PubMed Web of Science ®Google Scholar
• Grayson C, Chapple JP, Willison KR et al. In vitro analysis of aminoglycoside therapy for the Arg120stop nonsense mutation in RP2 patients. J. Med. Genet.39(1), 62–67 (2002).
   PubMed Web of Science ®Google Scholar
• Keeling KM, Brooks DA, Hopwood JJ et al. Gentamicin-mediated suppression of Hurler syndrome stop mutations restores a low level of α-L-iduronidase activity and reduces lysosomal glycosaminoglycan accumulation. Hum. Mol. Genet.10(3), 291–299 (2001).
   PubMed Web of Science ®Google Scholar
• Nejsum LN. The renal plumbing system: aquaporin water channels. Cell. Mol. Life Sci.62(15), 1692–1706 (2005).
   PubMedGoogle Scholar
• Robben JH, Sze M, Knoers NV, Deen PM. Rescue of vasopressin V2 receptor mutants by chemical chaperones: specificity and mechanism. Mol. Biol. Cell17(1), 379–386 (2006).
   PubMed Web of Science ®Google Scholar
• Schöneberg T, Yun J, Wenkert D, Wess J. Functional rescue of mutant V2 vasopressin receptors causing nephrogenic diabetes insipidus by a co-expressed receptor polypeptide. EMBO J.15(6), 1283–1291 (1996).
   Google Scholar
• Schöneberg T, Sandig V, Wess J, Gudermann T, Schultz G. Reconstitution of mutant V2 vasopressin receptors by adenovirus-mediated gene transfer. Molecular basis and clinical implication. J. Clin. Invest.100(6), 1547–1556 (1997).
   Google Scholar
• Barak LS, Oakley RH, Laporte SA, Caron MG. Constitutive arrestin-mediated desensitization of a human vasopressin receptor mutant associated with nephrogenic diabetes insipidus. Proc. Natl Acad. Sci. USA98(1), 93–98 (2001).
   PubMed Web of Science ®Google Scholar
• Ma T, Yang B, Gillespie A et al. Severely impaired urinary concentrating ability in transgenic mice lacking aquaporin-1 water channels. J. Biol. Chem.273(8), 4296–4299 (1998).
   PubMed Web of Science ®Google Scholar
• Ma T, Song Y, Yang B et al. Nephrogenic diabetes insipidus in mice lacking aquaporin-3 water channels. Proc. Natl Acad. Sci. USA97(8), 4386–4391 (2000).
   PubMed Web of Science ®Google Scholar
• Ma T, Yang B, Gillespie A et al. Generation and phenotype of a transgenic knockout mouse lacking the mercurial-insensitive water channel aquaporin-4. J. Clin. Invest.100(5), 957–962 (1997).
   PubMed Web of Science ®Google Scholar
• Lorenz JN, Baird NR, Judd LM et al. Impaired renal NaCl absorption in mice lacking the ROMK potassium channel, a model for type II Bartter’s syndrome. J. Biol. Chem.277(40), 37871–37880 (2002).
   Google Scholar
• Lu M, Wang T, Yan Q et al. Absence of small conductance K+ channel (SK) activity in apical membranes of thick ascending limb and cortical collecting duct in ROMK (Bartter’s) knockout mice. J. Biol. Chem.277(40), 37881–37887 (2002).
   PubMed Web of Science ®Google Scholar
• Takahashi N, Chernavvsky DR, Gomez RA et al. Uncompensated polyuria in a mouse model of Bartter’s syndrome. Proc. Natl Acad. Sci. USA97(10), 5434–5439 (2000).
   PubMedGoogle Scholar
• Uchida S, Marumo F. Severely impaired urine-concentrating ability in mice lacking the CLC-K1 chloride channel. Exp. Nephrol.8(6), 361–365 (2000).
   Google Scholar
• Akizuki N, Uchida S, Sasaki S, Marumo F. Impaired solute accumulation in inner medulla of Clcnk1-/- mice kidney. Am. J. Physiol. Renal Physiol.280(1), F79–F87 (2001).
   PubMed Web of Science ®Google Scholar
• Ho HT, Chung SK, Law JW et al. Aldose reductase-deficient mice develop nephrogenic diabetes insipidus. Mol. Cell. Biol.20(16), 5840–5846 (2000).
   PubMed Web of Science ®Google Scholar
• Amlal H, Ledoussal C, Sheriff S, Shull GE, Soleimani M. Downregulation of renal AQP2 water channel and NKCC2 in mice lacking the apical Na+-H+ exchanger NHE3. J. Physiol.553(Pt 2), 511–522 (2003).
   Google Scholar
• Yanai K, Saito T, Kakinuma Y et al. Renin-dependent cardiovascular functions and renin-independent blood-brain barrier functions revealed by renin-deficient mice. J. Biol. Chem.275(1), 5–8 (2000).
   PubMed Web of Science ®Google Scholar
• Takahashi N, Lopez ML, Cowhig JE, Jr. et al. Ren1c homozygous null mice are hypotensive and polyuric, but heterozygotes are indistinguishable from wild-type. J. Am. Soc. Nephrol.16(1), 125–132 (2005).
   Google Scholar
• Kotelevtsev Y, Brown RW, Fleming S et al. Hypertension in mice lacking 11β-hydroxysteroid dehydrogenase type 2. J. Clin. Invest.103(5), 683–689 (1999).
   PubMed Web of Science ®Google Scholar
• Behr R, Brestelli J, Fulmer JT et al. Mild nephrogenic diabetes insipidus caused by Foxa1 deficiency. J. Biol. Chem.279(40), 41936–41941 (2004).
   Google Scholar
• Morishita T, Tsutsui M, Shimokawa H et al. Nephrogenic diabetes insipidus in mice lacking all nitric oxide synthase isoforms. Proc. Natl Acad. Sci. USA102(30), 10616–10621 (2005).
   Google Scholar